Diagnostic performance of CA125 , HE4 , ROMA, and CPH‐I in identifying primary ovarian cancer
Journal of Obstetrics and Gynaecology Research · 2023-03 · 49 (3) · 998-1006
DOI: 10.1111/jog.15540 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Obstetrics and Gynaecology Research, online erschienen am 06.01.2023. Verfasst von Hui-Jing Luo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Center, Tianjin Medical University General Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: the Science Foundation for Distinguished Young Scholars of Tianjin.
Abstract (Originalsprache)
Aims
To evaluate the ability of carbohydrate antigen 125 (CA125), human epididymis protein 4 (HE4), risk of ovarian malignancy algorithm (ROMA), and Copenhagen Index (CPH‐I) to identify primary ovarian cancer (OC) from borderline and benign ovarian tumors (OTs) and explore ideal cutoff points.
Methods
A total of 684 OTs containing 276 OC patients, 116 ovarian borderline OTs and 292 benign OTs patients who underwent surgery in our hospital were included. We retrospectively searched the results of CA125 and HE4 before patients' surgery from the hospital's electronic medical records system. ROMA and CPH‐I were calculated according to their menopausal status and age, respectively. Diagnostic performance of these four were assessed by drawing receiver operating characteristic (ROC) curves.
Results
CA125, HE4, ROMA, and CPH‐I were all significantly higher in OC women compared with borderline OTs ( p < 0.001), followed by benign OTs ( p < 0.001). Area under the curves (AUCs) for distinguishing OC were 0.850 (0.818–0.882), 0.891 (0.865–0.916), 0.910 (0.888–0.933) and 0.906 (0.882–0.930), respectively, and the corresponding ideal cutoff values for CA125, HE4, ROMA, and CPH‐I were 132.5, 68.6, 23.8, and 6.4, respectively. The difference between ROMA and CPH‐I was not significant ( p = 0.97), but both were higher than CA125 and HE4 ( p < 0.05). HE4 showed a significantly higher AUC than CA125 ( p < 0.05). For postmenopausal women, CA125 performed equivalently to ROMA ( p = 0.73) and CPH‐I ( p = 0.91).
Conclusions
In identifying patients with OC, ROMA and CPH‐I outperformed single tumor marker. The diagnostic performance of HE4 was significantly higher than that of CA125. CA125 was more suitable for postmenopausal women.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory Center, Tianjin Medical University General Hospital, Tianjin, China.
- Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
- Department of Obstetrics and Gynecology, Tianjin Medical University General Hospital, Tianjin, China.
ORCID-Profile: Hui-Jing Luo
Förderung
- the Science Foundation for Distinguished Young Scholars of Tianjin
Zitieren
APA
Luo, H. J., Hu, Z. D., Cui, M., Zhang, X. F., Tian, W. Y., Ma, C. Q., Ren, Y. N., & Dong, Z. L. (2023). Diagnostic performance of CA125 , HE4 , ROMA, and CPH‐I in identifying primary ovarian cancer. Journal of Obstetrics and Gynaecology Research, 49(3), 998-1006. https://doi.org/10.1111/jog.15540
Vancouver
Luo HJ, Hu ZD, Cui M, Zhang XF, Tian WY, Ma CQ, et al. Diagnostic performance of CA125 , HE4 , ROMA, and CPH‐I in identifying primary ovarian cancer. Journal of Obstetrics and Gynaecology Research. 2023;49(3):998-1006. doi:10.1111/jog.15540
BibTeX
@article{Luo2023,
author = {Luo, Hui-Jing and Hu, Zhi-Dong and Cui, Ming and Zhang, Xiao-Fang and Tian, Wen-Yan and Ma, Chao-Qun and Ren, Ya-Nv and Dong, Zuo-Liang},
title = {Diagnostic performance of CA125 , HE4 , ROMA, and CPH‐I in identifying primary ovarian cancer},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2023},
volume = {49},
number = {3},
pages = {998--1006},
doi = {10.1111/jog.15540}
}
EUVIMED